German Pharma Giant Bayer Proposes $7.25 Billion Settlement Over Monsanto's Roundup Cancer Claims In US

Bayer AG (OTC:BAYRY) connected Tuesday projected a $7.25 cardinal colony to resoluteness thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer. The merchandise was primitively made by Monsanto, which Bayer acquired successful 2018 for much than $60 billion.

“Litigation uncertainty has plagued the company for years, and this settlement gives the institution a road to closure,” said Bayer CEO Bill Anderson. If approved by the court, the colony would trim imaginable vulnerability stemming from a aboriginal Supreme Court ruling, offering greater certainty to some Bayer and the patients pursuing damages.

Monsanto volition money the colony done capped yearly payments implicit up to 21 years, totaling arsenic overmuch arsenic $7.25 billion, and has separately agreed to settee further Roundup (glyphosate) cases nether confidential terms.

Don't Miss:

• This Energy Storage Company Already Has $185M successful Contracts—Shares Are Still Available

• Own the Characters, Not Just the Content: Inside a Fast-Growing Pre-IPO IP Company

The projected colony was filed successful Missouri’s St. Louis Circuit Court, wherever Bayer’s North American harvest subject part is based, and galore of the lawsuits were initiated.

The lawsuits claimed that the institution did not adequately pass users astir the imaginable non-Hodgkin lymphoma risks associated with Roundup’s cardinal ingredient, glyphosate.

This colony proposal comes arsenic the U.S. Supreme Court is preparing to hear arguments connected Bayer’s assertion that the U.S. Environmental Protection Agency’s approval of Roundup without a cancer informing should nullify authorities tribunal claims. The projected colony volition not interaction this case.

Trending: It’s nary wonderment Jeff Bezos holds implicit $250 cardinal successful creation — this alternate plus has outpaced the S&P 500 since 1995, delivering an mean yearly instrumentality of 11.4%. Here’s however mundane investors are getting started.

This projected colony follows different ineligible wins for Monsanto. In May 2024, Bayer’s Monsanto portion secured a important triumph erstwhile a Washington authorities appeals tribunal overturned a $185 cardinal verdict against the institution implicit chemic contamination astatine a Seattle-area school. The archetypal lawsuit, brought by 3 teachers who claimed they suffered encephalon harm from vulnerability to now-banned chemicals called polychlorinated biphenyls (PCBs), dates backmost to 2021 erstwhile Monsanto spinoff Pharmacia was recovered liable.

In December, Bayer secured backing from the Trump medication to curb U.S. lawsuits implicit its Roundup weedkiller, arsenic U.S. Solicitor General D. John Sauer urged the Supreme Court to bounds state-law claims, arguing they are preempted by national pesticide regulations. CEO Anderson welcomed the move, calling it a cardinal measurement toward regulatory clarity for farmers and informing that misapplication of national instrumentality could endanger entree to cultivation innovation and broader U.S. investment.